Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by A.L. Voisin
Infectious Complications Associated With the Use of Immune Checkpoint Inhibitors in Oncology: Reactivation of Tuberculosis After Anti PD-1 Treatment
Clinical Microbiology and Infection
Medicine
Infectious Diseases
Microbiology
Related publications
Immune Checkpoint Inhibitors in the Treatment of Virus-Associated Cancers
Journal of Hematology and Oncology
Cancer Research
Oncology
Hematology
Molecular Biology
Robust Antitumor Effects of Combined Anti-Cd4-Depleting Antibody and Anti-Pd-1/Pd-L1 Immune Checkpoint Antibody Treatment in Mice
Cancer immunology research
Cancer Research
Immunology
The Safety and Tolerability of Combined Immune Checkpoint Inhibitors (Anti-Pd-1/Pd-L1 Plus Anti-Ctla-4): A Systematic Review and Meta-Analysis
BMC Cancer
Cancer Research
Oncology
Genetics
Review of Cancer Treatment With Immune Checkpoint Inhibitors
Wiener Klinische Wochenschrift
Medicine
Pd-1 Immune Checkpoint Blockade Improves Anti-Cd20 Based Immunotherapy in Follicular Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
The Current Status of Immune Checkpoint Inhibitors in Neuro-Oncology: A Systematic Review
Cancers
Cancer Research
Oncology
HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-Pd-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment
Journal of Cancer
Oncology
Possible Abscopal Effect in Urothelial Carcinoma of the Upper Urinary Tract After Treatment With Immune Checkpoint Inhibitors
IJU Case Reports
Role of Immune Checkpoint Inhibitors in Gastrointestinal Cancer Treatment
Memo - Magazine of European Medical Oncology
Oncology
Hematology